TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.
TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.
David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...
Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 51,813 call options on the company. This is an increase of approximately ...
Tempus AI , Inc. (NASDAQ: TEM )董事David R. Epstein近期出售了370股该公司A类普通股。这些股票于2025年2月3日以平均每股$53.31的价格售出,总价值约$19,724。此后,TEM股价已上涨至$69.18,这家市值$97.4亿的公司年初至今已实现105%的显著涨幅。 InvestingPro ...
Tempus AI, known for its AI-driven precision medicine,... Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price target ...